The Dow Jones Industrial Average experienced volatility this year, facing multiple headwinds. Even so, a few stocks listed in the index performed well. Here's a look at four of them.

Pfizer and Moderna stocks are breaking out to the upside. Here's how to trade both names now, even as the market swoons.

Moderna and Merck hailed preliminary results from a combination therapy as a breakthrough, but there are important nuances to consider.

Here's why I see another rally before the weekend, even amid the messiness, and a bump for Amazon.

Moderna cautioned Thursday that $2 billion to $3 billion of its vaccine sales could be pushed into next year amid broader supply chain challenges.

7investing.com's resident biotech Ph.D., Dana Abramovitz, shares some valuable lessons about what to look for when investing in this space.

"We continue to execute on our strategy, invest in leading-edge science and drive innovation," said CEO Robert Davis.

Better-than-expected earnings for a host of Dow components had the average moving higher Thursday, but Meta's collapse put tech in the red.

A vaccine candidate from Vaxcyte appears to offer better protection against bacterial infections than the Prevnar franchise from Pfizer.

The troubled retailer has taken another major step to try to stave off closure.

“2022 was a strong year for AMD as we delivered best-in-class growth and record revenue despite the weak PC environment in the second half of the year," said CEO Lisa Su

Wall Street extended the S&P 500's solid January gains Tuesday as investors sorted through a wave of corporate earnings ahead of tomorrow's crucial Fed rate decision.